Corvus Pharmaceuticals, Inc.
NASDAQ:CRVSBiotechnology
-$0.19 today
- Market cap
- $859.56M
- Beta
- 0.84
- P/E (TTM)
- -24.1
- EPS (TTM)
- -$0.49
Volume 0.99M
Average 1.49M
CRVS Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Corvus Pharmaceuticals, Inc.NASDAQ: CRVS
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization grows in line with its trailing trend
Q1 FY2026 depreciation & amortization of $29K rose 31.8% year over year, behind the +33.3% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 11.5% from the prior quarter. Over 3 fiscal years it compounded at -34.1% a year.
Context
- Depreciation & amortization increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from +31.8% toward the trailing-twelve-month pace of +33.3%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 105K USD
- Year-over-year change
- +23.5%
- 4-year CAGR
- -30.9%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 105K | +23.5% |
| FY2024 | 2024-12-31 | 85K | -43.7% |
| FY2023 | 2023-12-31 | 151K | -58.9% |
| FY2022 | 2022-12-31 | 367K | -20.2% |
| FY2021 | 2021-12-31 | 460K | — |
Depreciation & Amortization vs competitors
How CRVS compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +33.3% is the 2nd highest of 8, against a peer median of -7.1%.
- Over three fiscal years its annual growth of -34.1% compares with a peer median of -22.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $10M USD | +0.0% | +18.6% | 8.5% | |
| LTM Mar 2026 | $6.94M USD | -7.1% | -22.5% | 4.4% | |
| FY2025 | €5.09M EUR | +155.3% | -51.8% | 182.7% | |
| LTM Mar 2026 | $4.93M USD | +2.3% | +2.0% | 10.5% | |
| LTM Mar 2026 | $1.03M USD | -39.0% | -38.3% | 2.9% | |
| LTM Jun 2024 | $515.94K USD | — | -25.9% | 63.2% | |
| LTM Mar 2026 | $468K USD | -128.3% | — | — | |
| LTM Jun 2026 | $129K USD | -88.2% | — | 0.2% | |
| LTM Mar 2026 | $112K USD | +33.3% | -34.1% | — | |
| LTM Dec 2025 | $0 USD | — | -0.5% | 0.0% | |
| Peer median (excluding CRVS) | — | -7.1% | -22.5% | 6.5% | |
Competitors are the stored peer set for CRVS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (43.24M) | (41.31M) | (27.03M) | (62.29M) | (15.28M) |
| Depreciation & Amortization | 460K | 367K | 151K | 85K | 105K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 4.23M | 2.69M | 2.15M | 3M | 5.33M |
| Change in Working Capital | (3.24M) | 1.41M | (3.59M) | (1.65M) | 3.58M |
| Accounts Receivables | (507K) | (81K) | 562K | (49K) | 38K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (1.9M) | 411K | (451K) | 1.06M | (91K) |
| Other Working Capital | (827K) | 1.08M | (3.71M) | (2.66M) | 3.63M |
| Other Non-Cash Items | 5.07M | 9.81M | 4.39M | 35.43M | (26.53M) |
| Operating Cash Flow | (36.72M) | (27.02M) | (23.94M) | (25.42M) | (32.8M) |
| Capital Expenditures | (5K) | (269K) | (34K) | 0 | (174K) |
| Acquisitions (Net) | (21.57K) | 22K | 0 | 5K | 0 |
| Purchases of Investments | (9.36M) | (66.19M) | (47.05M) | (70.12M) | (91.75M) |
| Sales of Investments | 30.92M | 43.16M | 62.62M | 42.63M | 84.13M |
| Other Investing Activities | 21.57K | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 21.56M | (23.28M) | 15.54M | (27.48M) | (7.8M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 60.94M | 0 | 7.84M | 16.41M | 36.43M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 1.22M | 0 | 12K | 32.62M | 0 |
| Financing Cash Flow | 62.16M | 0 | 7.86M | 49.03M | 36.43M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 47M | (50.3M) | (539K) | (3.88M) | (4.16M) |
| Free Cash Flow | (36.72M) | (27.29M) | (23.97M) | (25.42M) | (32.97M) |
Corvus Pharmaceuticals, Inc.
NASDAQ:CRVS
Intrinsic Alpha fair value
Locked
Current Price
$10.19
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.